ARAY - Accuray Incorporated

NasdaqGS - NasdaqGS Real-time price. Currency in USD
5.05
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close5.05
Open5.00
Bid0.00 x 0
Ask5.15 x 400
Day's range4.95 - 5.10
52-week range3.60 - 6.15
Volume151,801
Avg. volume811,703
Market cap430.731M
Beta2.46
PE ratio (TTM)N/A
EPS (TTM)-0.29
Earnings date30 Apr 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.20
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Accuray to Bring Patient-First Cancer Treatment Innovations to ESTRO 37

    Accuray Incorporated (Nasdaq:ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The meeting, to be held April 20-24, 2018, will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's innovative CyberKnife® and Radixact® Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.

  • Accuray Radixact Picked by India's Apollo for Cancer Treatment
    Zacks25 days ago

    Accuray Radixact Picked by India's Apollo for Cancer Treatment

    Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.

  • Accuray's CyberKnife Treats First Patient at Erasmus MC
    Zacks26 days ago

    Accuray's CyberKnife Treats First Patient at Erasmus MC

    Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.

  • Accuray Banks on Acquisition & Partnership Amid Competition
    Zacks26 days ago

    Accuray Banks on Acquisition & Partnership Amid Competition

    Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.

  • PR Newswire27 days ago

    Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy With the CyberKnife® System

    Accuray Incorporated (NASDAQ:ARAY) and Erasmus MC, the largest university medical center in the Netherlands, announced today that the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife® System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. "At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, MD, PhD, radiation oncologist, department of radiation oncology, Erasmus MC.

  • Accuray Gains on Radixact Unit, Solid Geographical Foothold
    Zackslast month

    Accuray Gains on Radixact Unit, Solid Geographical Foothold

    Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).

  • Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
    Zackslast month

    Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session

    The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.

  • How Accuray Has Performed Financially
    Market Realist2 months ago

    How Accuray Has Performed Financially

    In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.

  • How Much Is Accuray’s Target Market Expected to Grow?
    Market Realist2 months ago

    How Much Is Accuray’s Target Market Expected to Grow?

    To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.

  • What Analysts Recommend for Accuray in February 2018
    Market Realist2 months ago

    What Analysts Recommend for Accuray in February 2018

    Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.

  • A Look at Accuray’s Therapy Systems
    Market Realist2 months ago

    A Look at Accuray’s Therapy Systems

    Accuray’s (ARAY) CyberKnife systems are robotic systems that treat cancerous tumors through the delivery of radiosurgery. Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types. Based on a CT scanner platform, the Tomo therapy systems provide continuous delivery of radiation from 360 degrees around the patient or from beam angles specified by the clinician.

  • Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?
    Zacks2 months ago

    Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?

    Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire2 months ago

    Accuray's European AERO Academy Meeting: Innovation and Safety in the Field of Advanced Radiotherapy - Patients Come First

    Accuray Incorporated (NASDAQ:ARAY) announced today highlights from its 2018 European AERO™ (Accuray Exchange in Radiation Oncology) Academy conference held in Lisbon, Portugal on January 26th and 27th. "Accuray is firmly committed to providing our customers with access to clinical thought leadership and forums that encourage treatment innovation. The AERO Academy events, both in the US and in Europe, are a driving force behind our patient-first philosophy," said Joshua H. Levine, President and Chief Executive Officer at Accuray.

  • AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
    Zacks2 months ago

    AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

    Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.

  • Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
    Zacks2 months ago

    Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid

    Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.

  • athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
    Zacks3 months ago

    athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4

    Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.

  • Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
    Zacks3 months ago

    Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

    Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

  • Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong
    Zacks3 months ago

    Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong

    Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.

  • Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top
    Zacks3 months ago

    Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top

    In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.

  • Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
    Zacks3 months ago

    Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4

    Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.

  • McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View
    Zacks3 months ago

    McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View

    Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.

  • Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid
    Zacks3 months ago

    Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid

    Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.

  • Sirtex Medical: Varian Medical Systems’ Latest Acquisition
    Market Realist3 months ago

    Sirtex Medical: Varian Medical Systems’ Latest Acquisition

    Sirtex Medical Systems is an Australia-based life sciences company with a presence around the globe. The company is focused on interventional oncology therapies and is a global leader in radioembolization. Radioembolization is a minimally invasive therapy for the treatment of liver cancer.

  • IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
    Zacks3 months ago

    IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues

    IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.

  • 4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now
    Zacks3 months ago

    4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now

    Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes